Q4 2024 Neurocrine Biosciences Inc Earnings Call Transcript
Key Points
- Neurocrine Biosciences Inc (NBIX) reported record sales growth for INGREZZA in 2024, with an increase of approximately $475 million driven by increased volume and strong compliance.
- The company anticipates INGREZZA's sales to reach $2.5 billion to $2.6 billion in 2025, reflecting continued growth despite increased competitive pressure.
- CRENESSITY, a first-in-class treatment for congenital adrenal hyperplasia, received early FDA approval and has shown promising early launch dynamics.
- Neurocrine Biosciences Inc (NBIX) plans to expand its clinical stage pipeline from 12 to 18 programs by the end of 2025, indicating a robust and broad neuroscience pipeline.
- The company has a strong focus on research and development, with plans to initiate multiple Phase 3 programs in 2025, including Osavampator for major depressive disorder and NBI-568 for schizophrenia.
- Neurocrine Biosciences Inc (NBIX) faces increased competitive pressure and utilization management by payers, which has led to a slower growth trajectory for INGREZZA heading into 2025.
- The launch of CRENESSITY is expected to be measured initially due to delayed timing of reimbursement, patient flow frequency, and trialing by clinicians.
- The company anticipates a complex payer environment and competitive dynamics to impact INGREZZA's growth, with increased hurdles related to prior authorization.
- There is uncertainty regarding the long-term growth trajectory of INGREZZA, with ongoing debates about its peak sales potential in the US.
- Neurocrine Biosciences Inc (NBIX) acknowledges potential headwinds from its own sales force expansion, which may cause disruption before contributing to growth.
Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be standing by should you need any assistance.
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tuschla.
Thank you, and a good Thursday afternoon to everyone. Welcome to Neurocrine Biosciences' fourth quarter and full year 2024 earnings call. Joining me today are Kyle Gano, Chief Executive Officer; Matt Abernathy, Chief Financial Officer; Eric Benovich, Chief Commercial Officer; and Ivory Roberts, Chief Medical Officer.
Hearing our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We'll go to Q&A after repair remarks, and as is our custom, and with your help
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
